Skip to main content
Midas Edge

Sana Biotechnology, Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

SANA$2.43-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balance as of December 31, 2024223,923$22$1,855,318$14$(1,604,850)$250,504
Fees incurred related to common stock financings--(171)--(171)
Vesting of restricted stock960-----
Exercise of stock options58011,126--1,127
Stock-based compensation expense--7,022--7,022
Unrealized loss on marketable securities, net---(14)-(14)
Net loss----(49,389)(49,389)
Balance as of March 31, 2025225,463$23$1,863,295$-$(1,654,239)$209,079
Issuance of common stock from at the market offering, net of issuance costs of $174170-315--315
Exercise of pre-funded warrants4,445-----
Vesting of restricted stock203-----
Exercise of stock options102-148--148
Issuance of common stock related to employee stock purchase plan127-185--185
Stock-based compensation expense--6,629--6,629
Net loss----(93,800)(93,800)
Balance as of June 30, 2025230,510$23$1,870,572$-$(1,748,039)$122,556
Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders'
SharesAmountCapitalLossDeficitEquity
Balance as of December 31, 2023197,857$20$1,625,637$(60)$(1,338,091)$287,506
Issuance of common stock from at the market offering, net of issuance costs of $113150-1,037--1,037
Issuance of common stock from follow-on offering and accompanying pre-funded warrants, net of issuance costs of $9,74121,7732180,006--180,008
Vesting of restricted stock386-----
Exercise of stock options1,120-4,929--4,929
Stock-based compensation expense--9,092--9,092
Unrealized gain on marketable securities, net---45-45
Net loss----(107,475)(107,475)
Balance as of March 31, 2024221,286$22$1,820,701$(15)$(1,445,566)$375,142
Fees incurred related to common stock financings--(16)--(16)
Vesting of restricted stock52-----
Exercise of stock options548-2,361--2,361
Issuance of common stock related to employee stock purchase plan323-1,077--1,077
Stock-based compensation expense--11,380--11,380
Unrealized loss on marketable securities, net---(4)-(4)
Net loss----(50,291)(50,291)
Balance as of June 30, 2024222,209$22$1,835,503$(19)$(1,495,857)$339,649
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.